Gemcitabine — CPB 0958 | AETNA Coverage Update

Aetna modified CPB 0958 for gemcitabine, effective February 25, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its gemcitabine coverage policy under CPB 0958 to expand the list of covered indications and clarify criteria across more than two dozen cancer types. This Aetna gemcitabine coverage policy applies to commercial medical plans only — Medicare criteria live separately. If your oncology or infusion billing team submits claims with J9201, J9184, or J9196 alongside CPT codes 96413–96417, this update affects your charge capture and prior authorization workflows immediately.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Gemcitabine — CPB 0958
Policy Code	CPB 0958
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	Oncology, Hematology/Oncology, Gynecologic Oncology, Thoracic Oncology, Urology, Infusion Services
Key Action	Audit your oncology charge capture against the updated indication list and confirm ICD-10 diagnosis codes align with Aetna's expanded covered categories before submitting claims

---

Aetna Gemcitabine Coverage Criteria and Medical Necessity Requirements 2026

Aetna considers gemcitabine medically necessary across a wide range of solid tumors and hematologic malignancies. The coverage policy is broad, but it is not unlimited. Every indication has its own criteria, and several require specific staging or treatment history before Aetna will approve coverage.

CPB 0958 refers to the covered branded gemcitabine product as Avgemsi. The HCPCS code table lists J9184 as "gemcitabine hydrochloride (avyxa), 200 mg" and J9196 as "gemcitabine hydrochloride (accord), 200 mg," while J9201 covers generic gemcitabine hydrochloride at 200 mg. There is a discrepancy between the Avgemsi brand name in the policy text and the Avyxa product name in the J9184 code description. Confirm the correct product-to-code mapping with your pharmacy and Aetna directly before billing.

The most commonly billed indications include pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer (including urothelial carcinoma of the prostate and transitional cell carcinoma of the urinary tract), and ovarian, fallopian tube, and primary peritoneal cancers. For breast cancer, CPB 0958 limits coverage to members with no response to preoperative systemic therapy, or those with recurrent or metastatic disease. Coverage for breast cancer is limited to those specific disease states as stated in CPB 0958.

Several indications carry disease-state restrictions. Bone cancer coverage is limited to Ewing's sarcoma and osteosarcoma — but only for relapsed, progressive, refractory, or metastatic disease. Kidney cancer requires relapsed or metastatic status. Hodgkin lymphoma coverage for nodular lymphocyte-predominant disease requires progressive, relapsed, or refractory status. If your documentation does not reflect these staging requirements, expect a claim denial.

Prior authorization requirements are not explicitly detailed within the public CPB summary, but Aetna's standard commercial oncology process applies. Confirm prior auth requirements with the specific member's plan before initiating treatment. Reimbursement for gemcitabine infusions runs through CPT codes 96413–96417 — both the drug codes and administration codes are tied directly to this coverage policy.

---

Aetna Gemcitabine Exclusions and Non-Covered Indications

This coverage policy is heavily coverage-positive — Aetna lists more than two dozen approved indications. The policy does not enumerate a separate "not covered" list in the same way some other CPBs do. That is worth noting, because it means denials will typically come from diagnosis-level mismatches, not blanket exclusions.

The real exposure here is specificity. If you bill a broad ICD-10 code that doesn't match the covered subtype — say, a general ovarian cancer code when Aetna requires documentation of advanced, persistent, or recurrent disease — the claim will be denied on medical necessity grounds. The same applies to breast cancer claims that lack documentation of no response to preoperative systemic therapy, or recurrent or metastatic status.

Vaginal cancer coverage is noted in the policy summary but the criteria were truncated in available documentation. If your team treats patients with vaginal cancer and plans to bill gemcitabine, verify the specific coverage criteria directly in CPB 0958 on Aetna's portal before submitting.

---

Coverage Indications at a Glance

---

Aetna Gemcitabine Billing Guidelines and Action Items 2026

The effective date is February 25, 2026. If your team has not already reviewed this update, act now. Here's what to do:

Copy Action Items

If your practice has a high volume of gemcitabine claims across multiple indications — particularly soft tissue sarcomas, T-cell lymphomas, or the more unusual covered indications like ampullary adenocarcinoma — talk to your compliance officer before the effective date. The breadth of this policy is an asset, but only if your documentation and coding are airtight.

---

CPT, HCPCS, and ICD-10 Codes for Gemcitabine Under CPB 0958

Covered HCPCS Drug Codes (When Medical Necessity Criteria Are Met)

Code	Type	Description Copy
J9201	HCPCS	Injection, gemcitabine hydrochloride, 200 mg
J9184	HCPCS	Injection, gemcitabine hydrochloride (avyxa), 200 mg
J9196	HCPCS	Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg

Note: CPB 0958 refers to the covered branded gemcitabine product as Avgemsi. J9184 lists Avyxa in its HCPCS description. Confirm the correct product-to-code mapping with your pharmacy and Aetna directly.

Related Combination Agent HCPCS Codes

Chemotherapy Administration CPT Codes

Descriptions below are as provided in the CPB 0958 source policy. Refer to the AMA CPT codebook for full code descriptions and billing rules.

Key ICD-10-CM Diagnosis Codes

This policy covers 987 ICD-10-CM codes. The table below lists the primary categories. Map to the most specific code available for each member's diagnosis.

The full list of 987 covered ICD-10-CM codes is available in CPB 0958 at Aetna's policy portal. Review the complete list before updating your billing guidelines or charge capture.

---